- Home
- NAN vs ACIU Comparison
NAN vs ACIU Comparison
Compare NAN & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAN
- ACIU
- Stock Information
- Founded
- NAN 1999
- ACIU 2003
- Country
- NAN United States
- ACIU Switzerland
- Employees
- NAN N/A
- ACIU 161
- Industry
- NAN Investment Managers
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- NAN Finance
- ACIU Health Care
- Exchange
- NAN Nasdaq
- ACIU Nasdaq
- Market Cap
- NAN 353.4M
- ACIU 294.9M
- IPO Year
- NAN N/A
- ACIU 2016
- Fundamental
- Price
- NAN $11.47
- ACIU $2.98
- Analyst Decision
- NAN
- ACIU Strong Buy
- Analyst Count
- NAN 0
- ACIU 2
- Target Price
- NAN N/A
- ACIU $12.00
- AVG Volume (30 Days)
- NAN 74.6K
- ACIU 149.6K
- Earning Date
- NAN 01-01-0001
- ACIU 11-05-2024
- Dividend Yield
- NAN 4.37%
- ACIU N/A
- EPS Growth
- NAN N/A
- ACIU N/A
- EPS
- NAN N/A
- ACIU N/A
- Revenue
- NAN N/A
- ACIU $48,505,404.00
- Revenue This Year
- NAN N/A
- ACIU $85.33
- Revenue Next Year
- NAN N/A
- ACIU $80.69
- P/E Ratio
- NAN N/A
- ACIU N/A
- Revenue Growth
- NAN N/A
- ACIU 4097200.00
- 52 Week Low
- NAN $9.11
- ACIU $2.25
- 52 Week High
- NAN $11.34
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- NAN 54.09
- ACIU 53.19
- Support Level
- NAN $11.06
- ACIU $2.63
- Resistance Level
- NAN $11.68
- ACIU $2.90
- Average True Range (ATR)
- NAN 0.16
- ACIU 0.18
- MACD
- NAN 0.02
- ACIU 0.02
- Stochastic Oscillator
- NAN 65.97
- ACIU 80.85
About NAN Nuveen New York Quality Municipal Income Fund
Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal, New York State and New York City income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.